Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer
- 21 June 2012
- journal article
- review article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 107 (1), 15-22
- https://doi.org/10.1002/jso.23192
Abstract
Serum CA 19‐9 is the only FDA approved biomarker recommended for use in the routine management of pancreatic ductal adenocarcinoma (PDA). Over 2,000 biomarker studies related to pancreatic cancer appear in the literature, highlighting the need to discover and develop improved tests. Diagnostic biomarkers have implications for early detection of PDA, prognostic markers predict patient survival and recurrence patterns, and predictive markers can help personalize treatment regimens. J. Surg. Oncol. 2013;107:15–22.This publication has 83 references indexed in Scilit:
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerThe New England Journal of Medicine, 2011
- A phase 2 trial of gemcitabine, 5‐fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinomaCancer, 2010
- Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarrayBiochemical Pharmacology, 2010
- Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysisBritish Journal of Cancer, 2010
- The identification of phosphoglycerate kinase‐1 and histone H4 autoantibodies in pancreatic cancer patient serum using a natural protein microarrayElectrophoresis, 2009
- Association of GUCY2C Expression in Lymph Nodes With Time to Recurrence and Disease-Free Survival in pN0 Colorectal CancerJama-Journal Of The American Medical Association, 2009
- Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation studyNature Medicine, 2008
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsThe New England Journal of Medicine, 2002